23.8  -0.05 (-0.21%)		04-30 10:38
Open: 23.94 High: 23.94 Volume: 65,227		Pre. Close: 23.85 Low: 23.19 Market Cap: 306(M)

Short term
Mid term
Targets	6-month :	30.57	1-year :	33.95
Resists	First :	26.17	Second :	29.06
Pivot price	26.17
Supports	First :	21.5	Second :	17.88
MAs	MA(5) :	24.64	MA(20) :	26.07
	MA(100) :	22.43	MA(250) :	0
MACD	MACD :	0	Signal :	0.4
%K %D	K(14,3) :	10.7	D(3) :	17.8
RSI	RSI(14): 41.9
52-week	High :	33.2	Low :	13.88

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ EVMN ] has closed below the lower bollinger band by 0.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ EVMN ] is to continue within current trading range. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	25.59 - 25.73	25.73 - 25.85
Low:	23.12 - 23.31	23.31 - 23.46
Close:	23.57 - 23.85	23.85 - 24.08

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Thu, 30 Apr 2026
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Tue, 28 Apr 2026
Evommune, Inc.'s (NYSE:EVMN) Lock-Up Period To Expire on May 5th - MarketBeat

Fri, 24 Apr 2026
Evommune, Inc. Common Stock (NY: EVMN - FinancialContent

Thu, 23 Apr 2026
Evommune Shelf Registration Raises Dilution Questions After Strong Share Gains - Sahm

Fri, 17 Apr 2026
[Form 4] Evommune, Inc. Insider Trading Activity - Stock Titan

Fri, 17 Apr 2026
Evommune (EVMN) grants CFO 98,946 options at $26.77 strike - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NYSE
Sector: Healthcare
Industry: Biotechnology
Shares Out	36 (M)
Shares Float	20 (M)
Held by Insiders	7.2 (%)
Held by Institutions	91.7 (%)
Shares Short	3,310 (K)
Shares Short P.Month	3,030 (K)

EPS	-11.23
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	6.51
Profit Margin	0 %
Operating Margin	-623.7 %
Return on Assets (ttm)	-33.7 %
Return on Equity (ttm)	-54.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0.36
Sales Per Share	0.36
EBITDA (p.s.)	-2.22
Qtrly Earnings Growth	0 %
Operating Cash Flow	-76 (M)
Levered Free Cash Flow	-56 (M)

PE Ratio	-2.09
PEG Ratio	0
Price to Book value	3.59
Price to Sales	64.94
Price to Cash Flow	-11.05

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.